drugset / Trial / NCT04294511
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a open-lable, , single center, phase II clinical study. Target population is patients with locally resectable osteosarcoma. Study objective is to compare the efficacy and safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
Timeline
- Start
- 2019-12-26
- Primary completion
- 2021-03-16
- Completion
- 2023-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Ifosfamide | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | — |